Prostate cancer remains the most frequently diagnosed cancer among Australian men, yet the earliest molecular events leading to malignant transformation have remained poorly understood. Leveraging cutting-edge technologies including single-cell RNA sequencing and spatial transcriptomics, the research team led by Professor Alexander Swarbrick meticulously analyzed tumor tissue samples from 24 patients recently diagnosed with early localized prostate cancer. This powerful combination of techniques enabled characterization of not only the genetic activity within individual cells but also their precise spatial distribution within the tumor microenvironment, culminating in a comprehensive cellular atlas unprecedented in resolution and scope.

This atlas delineates eleven major cellular classes and more than fifty minor subtypes within prostate cancer tissue, shedding light on the diverse functional states and interactions of epithelial cells, fibroblasts, immune cells, and nervous system components. One of the most striking revelations is the identification of a novel fibroblast subtype, termed perineural cancer-associated fibroblasts (pnCAFs), which congregate around nerve fibers within the tumor mass. The discovery of pnCAFs is particularly significant as perineural invasion—tumor growth along or around nerves—has long been correlated with aggressive prostate cancer and poorer patient outcomes. These fibroblasts exhibit unique gene expression profiles suggestive of specialized communication machinery with peripheral nerves, hinting at an active role in tumor progression or metastasis.

Notably, the study highlights that many epithelial cells often judged histologically ‘normal’ already carry subtle genomic alterations indicative of pre-malignant transformation. Traditional pathology relies on microscopic assessment of cellular morphology to detect cancer, but these findings underscore that genetic changes occur invisibly well before obvious structural aberrations manifest. As such, the study paves the way for developing novel molecular diagnostics capable of identifying nascent cancerous states with higher sensitivity, potentially allowing intervention at an earlier disease stage when therapeutic outcomes are more favorable.

Professor Swarbrick emphasizes the transformative potential of these insights: “Our work presents a molecular narrative of prostate cancer development extending over several years. By revealing that a substantial fraction of supposedly healthy cells harbor early oncogenic mutations, we challenge the sufficiency of existing diagnostic paradigms, advocating for integration of molecular profiling tools into routine clinical workflows.” This paradigm shift aligns with the broader trend in oncology toward precision medicine, where therapies and monitoring are tailored to the patient’s molecular tumor landscape rather than solely morphological criteria.

Clinical implications resonate deeply with Professor Anthony Joshua, who underscores the urgent need for predictive biomarkers to discern which early-stage prostate cancers will progress aggressively. “Although current treatment modalities are effective for most prostate cancer patients, the heterogeneity of the disease mandates more refined stratification strategies. Understanding the sequence of genetic and cellular events that precipitate invasive cancer will empower clinicians to customize surveillance and treatment intensity, sparing low-risk patients from overtreatment while identifying those requiring early, aggressive intervention,” he explains.

The pioneering application of spatial transcriptomics provided a powerful lens to visualize the tumor ecosystem, revealing nuanced intercellular interactions shaping cancer evolution. Mapping gene expression in situ illuminated how fibroblasts, immune cells, and nerve-associated cells are spatially organized and potentially coordinate tumor growth and immune evasion. The close association of pnCAFs with peripheral nerve glial cells suggests complex crosstalk that may facilitate perineural invasion or nerve recruitment into the tumor microenvironment, a recognized hallmark of advanced prostate cancer.

Moving forward, the research team plans to expand their cohort to include a broader spectrum of patients, aiming to validate and refine their atlas while focusing on subpopulations of pre-malignant cells exhibiting cryptic genetic changes. Such efforts will pave the way to fully elucidate the temporal sequence of molecular alterations driving prostate tumorigenesis. Furthermore, mechanistic studies investigating the function of pnCAFs and their interactions with nerves could identify novel therapeutic targets, potentially disrupting perineural invasion pathways known to exacerbate clinical outcomes.

While these findings represent foundational scientific advancements rather than immediate clinical applications, the implications are far-reaching. With prostate cancer imposing significant health burdens globally, introducing molecular early detection assays and therapeutic strategies informed by this comprehensive atlas could revolutionize patient care. Early identification of mutation-harboring but morphologically normal cells would open a therapeutic window to nip cancer development in the bud, ultimately reducing morbidity and mortality associated with this pervasive disease.

This meticulous work was made possible through the Garvan St Vincent’s Prostate Cancer Biobank, the largest collection of prostate cancer tissue samples in the Southern Hemisphere, which has amassed specimens from over 16,000 patients over three decades. The biobank’s extensive repository enabled high-fidelity molecular characterization spanning diverse genetic backgrounds and disease stages, essential for constructing a representative and robust cellular atlas.

In summary, this study marks a significant leap in our understanding of prostate cancer biology by merging state-of-the-art single-cell genomic technologies with spatial tissue mapping. The identification of perineural cancer-associated fibroblasts and the revelation that many ostensibly normal cells carry early cancer-associated genetic changes challenge existing paradigms and open novel research and clinical frontiers. The atlas generated serves as a vital resource for the global scientific community, igniting fresh avenues for early diagnosis, risk assessment, and targeted therapies that could profoundly influence prostate cancer management worldwide.

Subject of Research: People

Article Title: Single-Cell and Spatial Transcriptomic Profiling Reveals Epithelial Functional States and Fibroblast Phenotypes in Hormone Therapy- Naïve Localized Prostate Cancer

News Publication Date: 25-Mar-2026

Web References:
https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-1202

References:
Cancer Research, DOI: 10.1158/0008-5472.CAN-25-1202

Image Credits: Garvan Institute

Keywords: Prostate cancer, Cancer, Prostate tumors, Epithelial cells, Single cell sequencing, RNA sequencing

Prostate cancer, particularly its castration-resistant form, represents a formidable clinical challenge due to its aggressive nature and relative insensitivity to conventional therapies. The tumor microenvironment (TME), a dynamic cellular ecosystem surrounding malignant cells, has garnered increasing attention for its critical role in tumor progression and immune evasion. Among the stromal components, CAFs emerge as potent regulators orchestrating the tumor’s evolutionary trajectory. Yet, the molecular identity and functional heterogeneity of CAFs specifically in CRPC had remained elusive until now.

Using cutting-edge single-cell RNA-sequencing (scRNA-seq) techniques, the study meticulously profiled CAF populations derived from CRPC tissues alongside those from primary prostate cancer (PCa). This innovative approach revealed a startling proliferation of CAFs within CRPC, underscoring them as a dominant cellular player in the resistant tumor niche. These CRPC-CAFs exhibited a distinct transcriptomic signature enriched for pathways associated with TGF-β signaling and extracellular matrix (ECM) remodeling, hallmark processes well known to facilitate tumor progression and stromal remodeling.

Delving deeper, the researchers employed gene regulatory network analysis to decode transcription factor activity within CRPC-CAFs, uncovering significant deviations from CAF profiles in primary PCa. This discovery suggests a profound reprogramming of fibroblast functionality in response to the resistant tumor milieu, equipping these cells with enhanced capabilities to modulate immune suppression and create a sanctuary for cancer cells from immune attack.

The clinical implications of these findings are profound. By correlating CAF abundance with patient data, the team identified a strong association between heightened CRPC-CAF levels and diminished recurrence-free survival, positioning these cells as a potent prognostic marker. Moreover, patients with elevated CRPC-CAFs demonstrated striking resistance to immunotherapy, a therapeutic modality that hinges on the immune system’s ability to recognize and eradicate cancer cells.

A closer examination of the immune landscape in tumors rich in CRPC-CAFs revealed an immunosuppressive microenvironment characterized by an influx of inhibitory immune cells and upregulation of immunosuppressive mediators. This immunologically “cold” niche likely underpins the reduced effectiveness of immune checkpoint inhibitors observed clinically, spotlighting CRPC-CAFs as central architects of immune escape.

Crucially, the study did not stop at descriptive biology. Employing a subcutaneous prostate cancer mouse model, researchers tested the therapeutic potential of disrupting TGF-β signaling within CRPC-CAFs. This intervention markedly synergized with anti-PD-1 checkpoint blockade, reinvigorating anti-tumor immune responses and significantly improving therapeutic outcomes. These preclinical results offer a compelling proof-of-concept that targeting stromal components, particularly CRPC-CAFs, can potentiate immunotherapy in resistant prostate cancers.

Importantly, the study positions TGF-β not merely as a tumor cell-intrinsic pathway but as a critical signaling axis within the tumor microenvironment that drives fibroblast-mediated immune suppression. This paradigm shift invites the development of combination therapies aiming at both malignant cells and their supportive stromal niches.

The application of single-cell technologies in this research exemplifies the power of resolving cellular heterogeneity in complex tumors. By capturing the nuances of CAF phenotypes at single-cell resolution, the study paves the way for precision oncology strategies that account for the tumor milieu’s stromal diversity and its impact on therapy responsiveness.

From a translational standpoint, quantifying CRPC-CAF abundance and their transcriptomic profiles could guide patient stratification, identifying individuals at heightened risk of therapeutic failure who may benefit from adjunct stromal-targeted treatments. Furthermore, these fibroblast-centric biomarkers may serve as early indicators of treatment efficacy or relapse.

This research also raises intriguing questions about the plasticity of CAFs in tumor evolution. Understanding the molecular cues driving their reprogramming in CRPC could uncover novel targets to intercept their conversion to immunosuppressive states, potentially halting or reversing tumor progression.

The elucidation of ECM remodeling pathways within CRPC-CAFs further implicates the extracellular environment as a modulator of immune cell infiltration and function, suggesting that stromal architecture itself may be a therapeutic vulnerability.

Collectively, these insights underscore the imperative to move beyond tumor-centric models of prostate cancer treatment and embrace the complexity of the TME. By intercepting the crosstalk between cancer cells and CAFs, future therapies stand to overcome the formidable barriers of immune evasion and treatment resistance.

In conclusion, this landmark study not only charts previously unrecognized transcriptional landscapes of CRPC-associated fibroblasts but also spotlights their critical role in dictating clinical outcomes and immunotherapy responsiveness. Interventions targeting the stromal compartment, particularly TGF-β signaling within CAFs, hold promise to revitalize immune-based therapies and improve prognosis for patients grappling with advanced prostate cancer.

As immuno-oncology continues to revolutionize cancer care, integrating stromal biology insights will be essential to surmount resistance mechanisms and unlock durable remissions. This research offers a blueprint for harnessing single-cell genomics to unravel TME complexity and tailor next-generation therapies in castration-resistant prostate cancer.

Subject of Research: The study focuses on the molecular and functional characterization of cancer-associated fibroblasts (CAFs) in castration-resistant prostate cancer (CRPC) using single-cell RNA sequencing, investigating their impact on prognosis and immunotherapy response.

Article Title: Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response

Article References:
Qiu, Y., Wang, Y., Liu, J. et al. Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response. BMC Cancer 25, 813 (2025). https://doi.org/10.1186/s12885-025-14212-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14212-x